In our study, pretreatment serum concentration of Ang-2 and bFGF as angiogenic factors show significant relationship with occurrence of the hepatobiliary adverse events or hypertension, which may represent regorafenib-targeting VEGFR1-3. Here, FGF2 is linked to Hypertension.